Global GMP Plasmid DNA Manufacturing Market Size is valued at USD 212.1 Million in 2024 and is predicted to reach USD 512.1 Million by the year 2034 at a 9.3% CAGR during the forecast period for 2025-2034.
Modern medicine heavily relies on plasmid DNA (PDNA). Plasmid DNA can be utilized either explicitly for a variety of therapeutic purposes, including gene therapy and the production of vaccine antigens, or indirectly for a broad range of research purposes. It is anticipated that the need for innovation in current manufacturing methods to meet the demand for acceptable products and their volume would offer substantial growth prospects for market players. A significant reason that propels the expansion of the GMP plasmid DNA manufacturing market is the rising number of gene therapy patients who choose to undergo the procedure.
The market for GMP plasmid DNA manufacturing will also benefit from growing government spending in the healthcare industry and an increase in older people. Plasmid DNA is in higher demand due to the need for effective illness treatment therapies. As a result, numerous businesses and research institutions are stepping up their R&D for cutting-edge treatments that target the disease's genomic origins. Due to the expanding research applications in genetic vaccination and gene therapy sectors, the market for GMP plasmid DNA manufacturing is expanding. The market is increasing favorably as more people are turning to gene therapy.
Several disorders may benefit from new potential treatments that gene therapy, a rapidly growing science, may provide. The increasing number of ties or collaborations between the different firms participating in this sector, which is anticipated to fuel the market growth, emphasizes the renewed interest in the manufacturing of plasmid deoxyribonucleic acid (DNA).
The GMP plasmid DNA manufacturing market is segmented based on products, types and applications. Based on Products, the market is segmented into Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno-Associated, Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others.Based on types, the market is segmented as pre-clinical therapeutics, clinical therapeutics, and marketed therapeutics. By application, the market is segmented into gene therapy, dan vaccines, immunotherapy, and others.
The clinical therapy category is expected to hold a major share of the global GMP plasmid DNA manufacturing market over the forecast period. Numerous plasmid DNA-based treatments are quickly moving past the clinical trial stage and will soon be available for purchase. The prevention or treatment of multiple illnesses, including cardiovascular diseases (CVDs) and cancer, including symptomatic patients, myeloid, acute ischemic, renal cell carcinoma, and coronary heart diseases, is being studied in current clinical studies based on plasmid DNA. Additionally, the role of plasmid DNA in clinical research implications for gene therapy and genetic vaccination is growing.
The gene therapy segment is projected to increase in the global GMP plasmid DNA manufacturing market. Gene therapy is used to alter cells and repair genetic material that is naturally flawed. Genetic problems have been successfully treated with cell and gene therapy. Gene therapies can also aid in diagnosing human viral illnesses and disorders. Additionally, the development of trustworthy and secure treatments for various ailments due to ongoing technological advancements is fueling the expansion of this market.
The North American GMP plasmid DNA manufacturing market is expected to register the highest market share in revenue soon. Increases in cancer patients, the desire for safe and effective medical procedures, and the existence of major market participants are the main factors propelling market expansion in the North American area. The GMP plasmid DNA manufacturing market will also be boosted by expanding technical advancements in the healthcare industry and newly discovered information on the use of plasmid DNA.
In addition, Asia Pacific is projected to grow rapidly in the global GMP plasmid DNA manufacturing market. Plasmid DNA manufacturing in the region will increase due to the region's aging population, increased disease rates among patients and the government's attempt to use plasmid DNA-based products.
· Aldevron (Danaher Corporation)
· VGXI, Inc.
· Charles River Laboratories
· Thermo Fisher Scientific
· Lonza Group AG
· Catalent Pharma Solutions
· PlasmidFactory GmbH & Co. KG
· Eurogentec (Kaneka Eurogentec S.A.)
· AGC Biologics
· GenScript ProBio (ProBio CDMO)
· TriLink BioTechnologies (Maravai / Azenta ecosystem)
· BioCina Pty Ltd.
· Richter BioLogics
· Andelyn Biosciences
· Cytovance Biologics
· WuXi Advanced Therapies (WuXi AppTec Group)
· Kaneka Corporation
· FUJIFILM Diosynth Biotechnologies
· Oxford Biomedica (OXB Solutions)
· Esco Aster (Esco Lifesciences Group)
· Samsung Biologics
· Novel Bio
· Akron Biotech
· Luminous BioSciences
· Center for Breakthrough Medicines (CBM / SK pharmteco)
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 212.1 Million |
| Revenue Forecast In 2034 | USD 512.1 Million |
| Growth Rate CAGR | CAGR of 9.3% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Manufacturing Type, By Application, By End User, By Therapeutic Area, By Scale of Operation |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Thermos Fisher Scientific, Cobra Bio, Rescript Probe, Wuxi Advanced Therapies, Charles River, Weisman Biomanufacturing, Bioscience, Lake Pharma, Alderton, Kaneka Neurogenetic S.A., Catalent Biologics, Neurogenetic, Nature Technology Corporation, Vector Builder, VGXI, Inc, Plasmid Factory, Delphi Genetics, Esko Aster, Bionian, Creative Biolabs, Vilene Biosciences, Patheon, Cognate Bio Services.. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global GMP Plasmid DNA Manufacturing Market Snapshot
Chapter 4. Global GMP Plasmid DNA Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:
5.2.1. Viral Vectors
5.2.1.1. Retroviral
5.2.1.2. Adenoviral
5.2.1.3. Lentiviral
5.2.1.4. Adeno-Associated
5.2.1.5. Others
5.2.2. Plasmid DNA
5.2.3. Non-viral
5.2.4. Lipid/polymer
5.2.5. Electroporation
5.2.6. Nanoparticles
5.2.7. Others
Chapter 6. Market Segmentation 2: by Manufacturing Type Estimates & Trend Analysis
6.1. by Manufacturing Type & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Manufacturing Type:
6.2.1. In-house Manufacturing
6.2.2. In-house Manufacturing
Chapter 7. Market Segmentation 2: by Scale of Operation Estimates & Trend Analysis
7.1. by Scale of Operation & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Scale of Operation:
7.2.1. Clinical-scale Manufacturing
7.2.2. Commercial-scale Manufacturing
Chapter 8. Market Segmentation 2: by Therapeutic Area Estimates & Trend Analysis
8.1. by Therapeutic Area & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:
8.2.1. Oncology
8.2.2. Infectious Diseases
8.2.3. Genetic Disorders
8.2.4. Cardiovascular & Metabolic Diseases
8.2.5. Neurological Disorders
Chapter 9. Market Segmentation 3: by Application Estimates & Trend Analysis
9.1. by Application & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
9.2.1. Gene Therapy
9.2.2. DNA Vaccines
9.2.3. Immunotherapy
9.2.4. Cell Therapy
9.2.5. Others
Chapter 10. GMP Plasmid DNA Manufacturing Market Segmentation 4: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.1.2. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
10.1.3. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.1.4. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.1.5. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.1.6. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.2. Europe
10.2.1. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.2.2. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
10.2.3. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.2.4. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.2.5. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.2.6. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.3. Asia Pacific
10.3.1. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.3.2. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
10.3.3. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.3.4. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.3.5. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.3.6. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.4. Latin America
10.4.1. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.4.2. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
10.4.3. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.4.4. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.4.5. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.4.6. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.5.2. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing Type, 2021-2034
10.5.3. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.5.4. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.5.5. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.5.6. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Aldevron (Danaher Corporation)
11.2.2. VGXI, Inc.
11.2.3. Charles River Laboratories
11.2.4. Thermo Fisher Scientific
11.2.5. Lonza Group AG
11.2.6. Catalent Pharma Solutions
11.2.7. PlasmidFactory GmbH & Co. KG
11.2.8. Eurogentec (Kaneka Eurogentec S.A.)
11.2.9. AGC Biologics
11.2.10. GenScript ProBio (ProBio CDMO)
11.2.11. TriLink BioTechnologies (Maravai / Azenta ecosystem)
11.2.12. BioCina Pty Ltd.
11.2.13. Richter BioLogics
11.2.14. Andelyn Biosciences
11.2.15. Cytovance Biologics
11.2.16. WuXi Advanced Therapies (WuXi AppTec Group)
11.2.17. Kaneka Corporation
11.2.18. FUJIFILM Diosynth Biotechnologies
11.2.19. Oxford Biomedica (OXB Solutions)
11.2.20. Esco Aster (Esco Lifesciences Group)
11.2.21. Samsung Biologics
11.2.22. Novel Bio
11.2.23. Akron Biotech
11.2.24. Luminous BioSciences
11.2.25. Center for Breakthrough Medicines (CBM / SK pharmteco) Other Prominent Players
By Manufacturing Type
· In-house Manufacturing
· Contract Manufacturing (CDMO Services)
Based on Types
Based on Applications
· Gene Therapy
· Cell Therapy
· DNA Vaccines
· Immunotherapy
· Others (e.g., protein expression, RNA production templates)
By Scale of Operation
· Clinical-scale Manufacturing
· Commercial-scale Manufacturing
By Therapeutic Area
· Oncology
· Infectious Diseases
· Genetic Disorders
· Cardiovascular & Metabolic Diseases
· Neurological Disorders
· Others (including Longevity / Anti-senescence Therapies)
By End User
· Biopharmaceutical & Biotechnology Companies
· Academic & Research Institutes
· Contract Research Organizations (CROs)
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa